Breaking News Instant updates and real-time market news.

CAG

Conagra Brands

$47.47

0.55 (1.17%)

, UA

Under Armour

$38.91

0.73 (1.91%)

10:22
10/14/16
10/14
10:22
10/14/16
10:22

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. ConAgra (CAG) upgraded to Outperform from Sector Perform at RBC Capital with analyst David Palmer citing valuation. 2. Under Armour (UA) upgraded to Overweight from Neutral at Piper Jaffray after the firm's semi-annual proprietary "Taking Stock With Teens" survey. 3. Domino's Pizza (DPZ) upgraded to Buy from Underperform at BofA/Merrill with analyst Gregory Francfort saying he believes Domino's has further growth ahead and will take share in the fragmented $34B U.S. pizza category. 4. TSMC (TSM) upgraded to Sector Weight from Underweight at Pacific Crest with analyst Michael McConnell citing a more favorable margin outlook and share gains at the 10 nm node. 5. Level 3 (LVLT) upgraded to Overweight from Neutral at JPMorgan with analyst Philip Cusick saying expectations have been lowered along with the share price. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

CAG

Conagra Brands

$47.47

0.55 (1.17%)

UA

Under Armour

$38.91

0.73 (1.91%)

DPZ

Domino's Pizza

$151.16

0.845 (0.56%)

TSM

TSMC

$31.25

0.72 (2.36%)

LVLT

Level 3

$46.09

1 (2.22%)

  • 18

    Oct

  • 18

    Oct

  • 21

    Oct

  • 25

    Oct

  • 03

    Nov

  • 16

    Nov

CAG Conagra Brands
$47.47

0.55 (1.17%)

08/03/16
MAXM
08/03/16
NO CHANGE
MAXM
Hain Celestial could be worth $63-$70 per share in a takeout, says Maxim
Maxim analyst Anthony Vendetti said Hain Celestial (HAIN) continues to have upside potential near-term and recent M&A activity in the sector substantiates his view that Hain would be a great addition for many companies looking to bolster their organic product lines. Vendetti said Danone's acquisition of Whitewave Foods (WWAV) implies a takeout valuation of Hain between $63-$70 per share and said potential suitors include Campbell Soup (CPB), Coca-Cola (KO), ConAgra Foods (CAG), General Mills (GIS), Kellogg (K), Kraft Heinz (KFT), Mondelez International (MDLZ), and PepsiCo (PEP).
10/12/16
MSCO
10/12/16
NO CHANGE
Target $53
MSCO
Overweight
ConAgra risk/reward attractive ahead of Investor Day, says Morgan Stanley
Morgan Stanley analyst Matthew Grainger said ConAgra risk/reward is still attractive ahead of the upcoming Investor Days despite recent outperformance. The analyst expects management to set expectations for further cost savings that support a further re-rating. Grainger expects pro forma earnings will likely imply modest dilution but sees the risk of a more substantial negative revision as unlikely. He sees multiple paths to value creation including its ability to lever up for M&A, selective divestitures, and potential for renewed focus on Lamb Weston. The analyst rates ConAgra an Overweight with a $53 price target.
10/14/16
RBCM
10/14/16
UPGRADE
RBCM
Outperform
ConAgra upgraded to Outperform from Sector Perform at RBC Capital
10/14/16
RBCM
10/14/16
UPGRADE
RBCM
Outperform
ConAgra upgraded based on valuation at RBC Capital
As noted earlier, RBC Capital upgraded ConAgra to Outperform from Sector Perform. Analyst David Palmer upgraded the stock based on valuation. Target to $54 from $50.
UA Under Armour
$38.91

0.73 (1.91%)

10/10/16
10/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Strong Buy from Market Perform at Raymond James with Elliot WIlbur saying the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. 2. Under Armour (UA) upgraded to Outperform from Market Perform at Wells Fargo with analyst Tom Nikic saying "noise" from the Sports Authority's bankruptcy is fading while distribution expansion could lead to sales re-acceleration over the next 12-18 months. 3. Deere (DE) and AGCO (AGCO) were upgraded to Outperform from Market Perform at Wells Fargo. 4. Dow Chemical (DOW) upgraded to Buy from Neutral at UBS with analyst John Roberts saying the merger with DuPont (DD) could gain regulatory approval and that the stock is "now too cheap to ignore." 5. Exelixis (EXEL) upgraded to Overweight from Neutral at Piper Jaffray with analyst Edward Tenthoff saying the data are "good enough" to file a supplemental new drug application and could drive off-label front-line RCC use. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/13/16
PIPR
10/13/16
UPGRADE
Target $44
PIPR
Overweight
Under Armour upgraded to Overweight after teen survey at Piper Jaffray
As previously reported, Piper Jaffray analyst Erinn Murphy upgraded Under Armour (UA) to Overweight from Neutral following the firm's semi-annual proprietary "Taking Stock With Teens" survey. The survey findings support on-going traction for Under Armour within footwear and the women's segment, noted Murphy, who raised her price target on the stock to $44 from $40. Based on the survey's results, other analysts at the firm also downgraded Estee Lauder (EL) to Neutral from Overweight and upgraded Zumiez (ZUMZ) to Overweight from Neutral.
10/13/16
PIPR
10/13/16
UPGRADE
PIPR
Overweight
Under Armour upgraded to Overweight from Neutral at Piper Jaffray
10/10/16
WELS
10/10/16
UPGRADE
WELS
Outperform
Under Armour upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Tom Nikic upgraded Under Armour to Outperform saying "noise" from the Sports Authority's bankruptcy is fading while distribution expansion could lead to sales reacceleration over the next 12-18 months. The analyst believes Under Armour's growth story is intact heading into 2017 and that its inventory levels are improving. Nikic raised his price target range for the shares to $44-$46 from $38-$42.
DPZ Domino's Pizza
$151.16

0.845 (0.56%)

06/22/16
06/22/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Perform from Outperform at Oppenheimer with analysts led by Colin Rusch saying they do not view the acquisition of Solar City (SCTY) as the best use of Tesla's capital and human resources given the potential returns on capital possible in the electric industry versus the potential leverage in Tesla's auto platform. 2. SolarCity downgraded to Hold from Buy at Stifel with analyst Sven Eenmaa saying the risk/reward looks balanced in the wake of Tesla's bid. 3. AMC Networks (AMCX) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Ryan Fiftal saying 2016 new show launches have missed expectations, making it unlikely the company can grow EBITDA beyond 2016 as declining Walking Dead ratings pressure the top-line. 4. ACADIA (ACAD) downgraded to Neutral from Buy at BofA/Merrill with the firm citing valuation. 5. McDonald's (MCD), Wendy's (WEN), Papa John's (PZZA) and Domino's Pizza (DPZ) downgraded to Neutral from Buy at Nomura. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/05/16
LBOW
07/05/16
NO CHANGE
Target $145
LBOW
Buy
Domino's Pizza Q2 comps above consensus, says Longbow
Longbow analyst Alton Stump's checks indicate Domino's Pizza's domestic franchised same-store-sales were up in a 7%-7.5% range in Q2, in line with his 7.3% franchised comp growth estimate but ahead of consensus of 6.2%. Stump reiterates his Buy rating and $145 price target on Domino's shares.
10/14/16
BOFA
10/14/16
UPGRADE
BOFA
Buy
Domino's Pizza upgraded to Buy from Underperform at BofA/Merrill
10/14/16
10/14/16
UPGRADE
Target $175

Buy
Domino's Pizza upgraded two notches on growth opportunity at BofA/Merrill
As previously reported, BofA/Merrill upgraded Domino's Pizza two notches to Buy from Underperform and raised its price target to $175 from $120. Analyst Gregory Francfort believes Domino's has further growth ahead and will take share in the fragmented $34B US pizza category. The analyst expects 7.3% domestic system sales growth over the next six years and said shares discount 6.7% growth. He expects Domino's sales growth to continue driven by modest growth in the quick service pizza category, general market share gains by large chains due to digital ordering advantages, remodeling and relocation upgrades, digital customer data lead following its loyalty rollout, and impressive management.
TSM TSMC
$31.25

0.72 (2.36%)

10/13/16
HSBC
10/13/16
DOWNGRADE
HSBC
Hold
TSMC downgraded to Hold from Buy at HSBC
10/04/16
SUSQ
10/04/16
UPGRADE
Target $28
SUSQ
Neutral
TSMC upgraded to Neutral at Susquehanna
As reported previously, Susquehanna analyst Mehdi Hosseini upgraded TSMC to Neutral from Negative. The analyst increased his estimates to reflect mild seasonality, continued elevation rates, minimal selling price erosion, and the company's dominance in the 10nm foundry market. Hosseini raised his price target to $28 from $20 on TSMC shares.
10/04/16
SUSQ
10/04/16
UPGRADE
SUSQ
Neutral
TSMC upgraded to Neutral from Negative at Susquehanna
10/14/16
PACS
10/14/16
UPGRADE
PACS
Sector Weight
TSMC upgraded to Sector Weight from Underweight at Pacific Crest
Pacific Crest analyst Michael McConnell upgraded TSMC to Sector Weight citing a more favorable margin outlook and share gains at the 10 nm node. The analyst views the stock's risk/reward as balanced at current levels.
LVLT Level 3
$46.09

1 (2.22%)

10/14/16
JPMS
10/14/16
UPGRADE
Target $55
JPMS
Overweight
Level 3 upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Philip Cusick upgraded Level 3 Communications to Overweight saying expectations have been lowered along with the share price. Further, he believes a capital return announcement in the form of a stock buyback could come either on the Q3 or Q4 earnings calls. The analyst lowered his price target for Level 3 to $55 from $60 and keeps an Overweight rating on the shares.
10/13/16
GSCO
10/13/16
DOWNGRADE
Target $55
GSCO
Buy
Level 3 downgraded to Buy from Conviction Buy at Goldman
Goldman analyst Brett Feldman removed Level 3 from the Conviction Buy List and lowered its price target to $55 from $64 on a reduced outlook for revenue growth and a lower target multiple. The analyst maintains a Buy rating and said the recent pullback in Level 3 shares increases the appeal of buybacks and, theoretically, the company could repurchase 60% of its stock over 5 years.
08/24/16
08/24/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Level 3 (LVLT) upgraded to Buy from Neutral at MoffettNathanson. 2. Hormel Foods (HRL) upgraded to Buy from Hold at Edward Jones. 3. Laredo Petroleum (LPI) upgraded to Overweight from Equalweight at Capital One with the firm saying it expects continued stock outperformance given the most recent Midland Basin hzl well results. 4. NetApp (NTAP) upgraded to Neutral from Sell at Goldman with analyst Simona Jankowski citing balanced risk/reward. 5. PDC Energy (PDCE) upgraded to Overweight at Stephens with analyst Ben Wyatt citing the company's agreement to acquire two privately held companies in a "transformative" deal that includes approximately 57,000 net acres in Texas. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/24/16
MOFT
08/24/16
UPGRADE
MOFT
Buy
Level 3 upgraded to Buy from Neutral at MoffettNathanson

TODAY'S FREE FLY STORIES

CELG

Celgene

$117.63

-1.24 (-1.04%)

22:25
12/04/16
12/04
22:25
12/04/16
22:25
Conference/Events
Celgene to hold an analyst and investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

AAPL

Apple

$109.90

0.41 (0.37%)

, ALNY

Alnylam

$41.57

-0.01 (-0.02%)

21:48
12/04/16
12/04
21:48
12/04/16
21:48
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

AAPL

Apple

$109.90

0.41 (0.37%)

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

BLCM

Bellicum Pharmaceuticals

$18.72

1.74 (10.25%)

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

UTX

United Technologies

$108.22

0.74 (0.69%)

RXN

Rexnord

$20.27

-0.72 (-3.43%)

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

EVC

Entravision

TJX

TJX

$77.10

-0.57 (-0.73%)

FL

Foot Locker

$74.23

0.55 (0.75%)

DE

Deere

$101.50

-1.2 (-1.17%)

ARCH

Arch Coal

$79.32

1.6 (2.06%)

ELY

Callaway Golf

$11.68

-0.3 (-2.50%)

GME

GameStop

$24.27

-0.37 (-1.50%)

AEO

American Eagle

$16.17

-0.57 (-3.41%)

JCP

J.C. Penney

$9.81

0.28 (2.94%)

GOOG

Alphabet

$750.50

2.58 (0.34%)

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

MRK

Merck

$61.13

0.37 (0.61%)

DIS

Disney

$98.50

-0.44 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

  • 09

    Jan

  • 15

    Jan

  • 08

    Mar

  • 13

    Mar

TRIP

TripAdvisor

$46.46

-0.7 (-1.48%)

21:40
12/04/16
12/04
21:40
12/04/16
21:40
Upgrade
TripAdvisor rating change  »

TripAdvisor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTXS

Citrix

$85.62

0.15 (0.18%)

21:40
12/04/16
12/04
21:40
12/04/16
21:40
Upgrade
Citrix rating change  »

Citrix upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 08

    Dec

XOM

Exxon Mobil

$87.04

-0.2 (-0.23%)

21:12
12/04/16
12/04
21:12
12/04/16
21:12
Periodicals
Trump widens Secretary of State search, will interview Exxon Mobil CEO, WSJ says »

President-elect Donald…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

21:08
12/04/16
12/04
21:08
12/04/16
21:08
Periodicals
Novartis CEO downplays possibility of Actelion bid, Reuters says »

Asked whether Novartis…

NVS

Novartis

$68.17

0.42 (0.62%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PCRFY

Panasonic

$10.58

0.19 (1.83%)

21:05
12/04/16
12/04
21:05
12/04/16
21:05
Periodicals
Panasonic eyes European headlight maker ZKW, Nikkei says »

Panasonic plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$109.90

0.41 (0.37%)

21:03
12/04/16
12/04
21:03
12/04/16
21:03
Hot Stocks
Apple comments on U.S. autonomous cars policy, says 'excited' about potential »

The U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

20:46
12/04/16
12/04
20:46
12/04/16
20:46
Hot Stocks
Army says will not grant easement for Dakota Access Pipeline »

The Department of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

20:25
12/04/16
12/04
20:25
12/04/16
20:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

AGIO

Agios Pharmaceuticals

$56.97

-1.09 (-1.88%)

20:11
12/04/16
12/04
20:11
12/04/16
20:11
Hot Stocks
Agios Pharmaceuticals reports data on AG-348, AG-519 »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:59
12/04/16
12/04
19:59
12/04/16
19:59
Hot Stocks
Karyopharm reports updated Phase 2b STORM data »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ABBV

AbbVie

$59.43

0.27 (0.46%)

19:56
12/04/16
12/04
19:56
12/04/16
19:56
Hot Stocks
AbbVie reports data from two IMBRUVICA combination studies »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ABBV

AbbVie

$59.43

0.27 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

BPMC

Blueprint Medicines

$27.01

-0.99 (-3.54%)

19:50
12/04/16
12/04
19:50
12/04/16
19:50
Hot Stocks
Blueprint Medicines reports Phase 1 BLU-285 data »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

19:45
12/04/16
12/04
19:45
12/04/16
19:45
Hot Stocks
Incyte reports pooled analysis of five-year Jakafi data »

Incyte announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

GPRO

GoPro

$9.70

-0.12 (-1.22%)

19:42
12/04/16
12/04
19:42
12/04/16
19:42
Hot Stocks
GoPro releases $299 'Karma Grip' camera stabilizer »

GoPro announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:37
12/04/16
12/04
19:37
12/04/16
19:37
Hot Stocks
Karyopharm reports data from Phase 2 SAIL study »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:32
12/04/16
12/04
19:32
12/04/16
19:32
Hot Stocks
Acetylon reports preclinical ACY-957 data »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

GBT

Global Blood Therapeutics

$19.10

-0.1 (-0.52%)

19:30
12/04/16
12/04
19:30
12/04/16
19:30
Hot Stocks
Global Blood Therapeutics reports Phase 1/2 GBT440 data »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 14

    Dec

  • 15

    Dec

  • 19

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:27
12/04/16
12/04
19:27
12/04/16
19:27
Hot Stocks
Acetylon reports initial Phase 1a/b data for citarinostat in myeloma »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

XLRN

Acceleron

$36.29

1.25 (3.57%)

, CELG

Celgene

$117.63

-1.24 (-1.04%)

19:23
12/04/16
12/04
19:23
12/04/16
19:23
Hot Stocks
Acceleron, Celgene report updated data from Phase 2 luspatercept studies »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$36.29

1.25 (3.57%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

19:05
12/04/16
12/04
19:05
12/04/16
19:05
Hot Stocks
Alnylam reports Phase 2 data on fitusiran in hemophilia »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$122.96

0.95 (0.78%)

19:01
12/04/16
12/04
19:01
12/04/16
19:01
Hot Stocks
Alexion reports data from Phase 1/2 ALXN1210 study »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

LYV

Live Nation

$27.07

-0.44 (-1.60%)

18:58
12/04/16
12/04
18:58
12/04/16
18:58
Hot Stocks
Live Nation acquires 51% stake in Australia's Secret Sounds Group »

Live Nation Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$68.17

0.42 (0.62%)

18:45
12/04/16
12/04
18:45
12/04/16
18:45
Hot Stocks
Novartis reports Phase 2 data on CTL019 in leukemia »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.